




Exyte Group

Financial Statement 9M/2022 - Summary

November 9th, 2022



Key Figures 9M/2022*



* All figures are unaudited.

¹ Change year-on-year.

² Full-time equivalents as of September 30, 2022.


Figures at a Glance 9M/2022



in € million

	Sep. 1 - Sep. 30, 2022	Sep. 1 - Sep. 30, 2021	Growth
Order intake	6,474	5,132	26.1%
Sales	5,330	3,395	57.0%
Gross profit	429	260	65.0%
Gross profit margin in %	8.0	7.7	0.3PP
EBIT	295	175	68.6%
EBIT margin in %	5.5	5.2	0.3PP
Adjusted EBIT	308	178	73.0%
Adjusted EBIT margin in %	5.8	5.3	0.5PP
Adjusted EBITDA	340	200	70.0%
Adjusted EBITDA margin in %	6.4	5.9	0.5PP
Group net profit	262	139	88.5%
Group net profit margin in %	4.9	4.1	0.8PP
No. of Employees (full-time equivalents at the end of period)	8,866	5,980	-
Cash flow from operating activities	770	441	-
Cash flow from investing activities	-49	32	-
Free cash flow	721	473	-
	Sep. 30, 2022	Dec. 31, 2021	
Order backlog	8,207	6,696	22.6%


Key Financials 9M/2022 I



- Strong increase in order intake driven by high demand from clients in all business segments.
 - Substantial order backlog of 8,207 Mio. € ensures future profitable sales growth.
-
- Significant increase of sales due to large major projects, especially in APAC and EMEA. The acquisition of CPS Group contributes sales of 131 Mio. € after 9 months in 2022.


Key Financials 9M/2022 II

adj. EBIT¹



- 9M/2022 adjusted EBIT reached 308 Mio. € with ATF projects being the main contributor.

adj. EBITDA



- Following the EBIT growth, adjusted EBITDA improved to 340 Mio. € after 9M/2022.

1) For explanation of adjusted EBIT, please see "Earnings Performance."


Order Intake by Region 9M/2022

Order intake by region¹

in € million

	9M/2022	9M/2021
APAC	3,739	2,263
EMEA	1,529	2,354
AMER	725	291
T&S	788	336

in % (previous year)



¹ Before consolidation of the regions.

High order intake

- Noticeable increase in order intake on a year-on-year comparison, with APAC being the largest contributor to the Group's order intake, followed by EMEA.
- Increase of order intake in APAC due to the award of large projects in Malaysia, China, Singapore and Taiwan.
- Order intake in AMER substantially higher compared to 9M/2021 due to the award of a major project from a confidential client.
- T&S order intake contribution more than doubled compared to the first three quarters of last year driven by the acquisition of CPS Group, amongst others.

Order Intake by Business Segment 9M/2022


Strong growth in ATF and DTC

- ATF business segment remains strongest segment with a share of almost 86% of order intake. Significant projects have been awarded in Malaysia, China, Singapore and the US.
- BLS business segment is up 20% in order intake compared to previous year – executing a large mRNA competence center in Germany.
- The success of DTC continued due to major projects booked in Denmark, Taiwan and Israel.

Order intake by business segment

in € million	9M/2022	9M/2021
ATF	5,541	4,503
BLS	477	384
DTC	409	175
RSB	47	20

in % (previous year)




Sales by Region 9M/2022

Sales by region¹

in € million

	9M/2022	9M/2021
APAC	3,021	1,064
EMEA	1,572	1,813
AMER	353	343
T&S	555	280

in % (previous year)



¹ Before consolidation of the regions.

APAC and T&S with strong performances

- APAC with enormous sales increase especially in Singapore, Malaysia and China.
- EMEA's performance remains on a high level, due to large projects in Ireland, Germany and Israel.
- T&S nearly doubled sales compared to 9M/2021.

Sales by Business Segment 9M/2022


ATF continues to be the main growth driver

- Due to large scale semiconductor projects in all regions, the ATF business segment continues to grow on a year-on-year comparison.
- BLS business segment increased its sales due to the execution of major projects in Singapore and Malaysia.
- The sales increase of the DTC business segment is mainly driven by multiple projects in Israel, Germany and APAC region.

Sales by business segment

in € million	9M/2022	9M/2021
ATF	4,613	2,968
BLS	477	247
DTC	181	104
RSB	58	69

in % (previous year)



Earnings Performance 9M/2022



Adjusted EBIT¹

in € million

	9M/2022	9M/2021
Reported EBIT	295.3	174.7
Adjustments	13.1	3.7
of which due to restructuring measures	2.8	1.9
of which COVID-19 related adjustments	0.1	0.1
of which related to depreciation of PPA of CPS Group	5.0	0.0
of which other adjustments	5.2	1.7
Adjusted EBIT¹	308.4	178.4

Profitability improved

- Adjusted EBIT¹ (adjusted earnings before interest and taxes) increased considerably compared to 9M/2021.
- The adjusted EBIT margin improved to 5.8% in 9M/2022 (0.5PP higher than 9M/2021).

1) Adjusted EBIT is defined as the result from operating activities (earnings before interest and tax; EBIT) adjusted for income or expenses deriving from non-recurring effects. EBIT adjustments result from income or expenses related to the Exyte Group's reorganization, costs of restructuring measures, costs incurred due to site closures and relocations, effects on earnings from purchase price allocations or other income or expenses that are non-recurring in nature or are incurred outside the normal course of business, as well as COVID 19-related effects. Adjusted EBIT is used to determine profitability excluding non-recurring positive or negative effects, thus ensuring comparability between different reporting periods.

Outlook Financial Year 2022



Geopolitical tensions and economic uncertainties are affecting the global economy. Going forward, further disruptions in supply chains and negative impacts deriving from COVID-19 and other developments can not be completely ruled out.

We expect to outperform our financial targets reaching annual sales of around €7.0 billion by the end of 2022. In accordance with the increase in targeted sales, an increase in adjusted EBITDA and adjusted EBIT is expected – envisaging a forecasted adjusted EBITDA of approximately €450 million, respectively an adjusted EBIT of above €400 million. Incoming orders in 2022 are expected to be on a similarly high level as in 2021.

This presentation contains forward-looking statements that reflect our current view about future business and financial performance as well as future events or developments. Forward-looking statements are characterized by the use of words such as “expect,” “intend,” “plan,” “predict,” “assume,” “believe,” “estimate,” “anticipate,” and similar expressions. These statements are based on current expectations and assumptions made by the executive management of Exyte Group and are subject to many risks and uncertainties which are mainly beyond Exyte’s control. Should any of these risks or uncertainties materialize or any expectations or assumptions prove to be incorrect, the actual future results may be materially different from those described explicitly or implicitly in the relevant forward-looking statement. Therefore, Exyte does not guarantee any of these forward-looking statements and neither intends nor assumes any obligation to update or revise those in case of developments which differ from those anticipated.

Exyte Group accepts no liability for the accuracy and completeness of information provided in this presentation.



Exyte
René Ziegler
Corporate Communications & Investor Relations
Löwentorbogen 9b
70376 Stuttgart
Germany

T +49 711 8804 4606

ir@exyte.net